Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.5352W HIGH $9.12
Volume
344.33 K
Value Traded
267.56 K
Short % Float
4.81%
-17.58%Week
-14.05%1 Month
-3.65%3 Month
-47.25%6 Month
-91.23%5 Year
-99.25%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
41.99 M
EPS (TTM)
-1.03
P/E Ratio
-
Ent. Value
-12.10 M
Total Shares
9.95 M
Float Shares
9.56 M
Insiders
3.96%
Institutions
56.33%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SCYX Catalyst Timeline
Dated clinical, regulatory and corporate events for SCYNEXIS, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for SCYNEXIS, Inc.
648Total events
17Upcoming
141Tier-1 (high impact)
2010 to 2035Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutSCY-770Clinical Data
SCYNEXIS announces completion and results of Phase 1 study of SCY-770 in healthy participants
Autosomal Dominant Polycystic Kidney Disease (ADPKD)source ↗
●Trial CompletionSCY-770Trial
Completion of Phase 1 study of SCY-770
Autosomal Dominant Polycystic Kidney Disease (ADPKD)source ↗
▲Grant / FundingSCY-247Corporate
SCYNEXIS awarded BARDA contract of up to ~$214M for SCY-247 development
invasive fungal infectionssource ↗
●Management ChangeCorporate
Todd Minga, M.D. appointed Senior Vice President, Research & Development
▼Equity OfferingCorporate
Announced $40.0 million private placement with potential additional $52.2 million from warrant exercise
◆AcquisitionPXL-770Corporate
SCYNEXIS acquires PXL-770 (now SCY-770) from Poxel S.A.
Autosomal Dominant Polycystic Kidney Disease (ADPKD)source ↗
◆AcquisitionSCY-770Corporate
Acquisition of PXL-770 (now SCY-770) from Poxel S.A.
autosomal dominant polycystic kidney disease (ADPKD)source ↗
▲First Patient DosedSCY-247Trial
First participants dosed in Phase 1 SAD/MAD trial of IV SCY-247
invasive candidiasissource ↗
◆Poster PresentationSCY-247Presentation
Poster presentation of SCY-247 antifungal activity at IMARI
drug-resistant fungal infectionssource ↗
◆Oral PresentationSCY-247Presentation
Oral presentation of SCY-247 antifungal activity at IMARI
drug-resistant fungal infectionssource ↗
▲QIDPSCY-247Designation
FDA grants QIDP designation for SCY-247
serious or life-threatening infectionssource ↗
▲Fast Track DesignationSCY-247Designation
FDA grants Fast Track designation for SCY-247
serious or life-threatening infectionssource ↗
◆Reverse Stock SplitCorporate
Nasdaq grants 180-day extension to regain minimum bid price compliance; reverse stock split possible
●Timing GuidanceBREXAFEMMEApprovedPresentation
Transfer of BREXAFEMME NDA to GSK expected by end of 2025
vulvovaginal candidiasis (VVC) and refractory VVC (rVVC)source ↗
◆Milestone PaymentIbrexafungerpApprovedCorporate
Additional $20M milestone payment due upon six-month anniversary of new patient dosing in MARIO
▲NDA SubmissionBREXAFEMMEApprovedRegulatory Filing
Completed transfer of BREXAFEMME NDA to GSK
vulvovaginal candidiasis (VVC) and refractory vulvovaginal candidiasis (rVVC)source ↗
▲Preclinical PoCPreclinical
Federal grant awarded to CETR for development of next-generation fungerp candidates
resistant fungal infectionssource ↗
◆Milestone PaymentIbrexafungerpApprovedCorporate
$20 million milestone payment from GSK triggered by six-month anniversary of dosing
◆Partnership / LicenseCorporate
SCYNEXIS and GSK resolve disagreement; SCYNEXIS to receive $22M payment and wind down MARIO study
▼Trial DiscontinuedTrial
Phase 3 MARIO study discontinued; wind-down activities to commence
invasive candidiasissource ↗
▲Full ResultsSCY-247Clinical Data
Positive results from Phase 1 SAD and MAD study of SCY-247
invasive fungal infectionssource ↗
◆Poster PresentationSCY-247Presentation
Poster on three months of SCY-247 EUCAST MIC testing against Candida species at TIMM-12
Candida species infectionssource ↗
◆Oral PresentationSCY-247Presentation
Oral presentation on in vitro activity of SCY-247 against C. auris including FKS1 mutants at TIMM-12
Candida auris infectionssource ↗
◆Poster PresentationSCY-247Presentation
Poster on in vitro activity of SCY-247 against Aspergillus spp. and L. prolificans at TIMM-12
Aspergillus spp. and Lomentospora prolificans infectionssource ↗
◆Oral PresentationPresentation
SCYNEXIS presentation at H.C. Wainwright 27th Annual Global Conference
▲Topline ReadoutSCY-247Clinical Data
Positive SAD/MAD data for oral SCY-247 announced
invasive fungal diseasesource ↗
▲PK PD DataSCY-247Clinical Data
Positive Phase 1 single- and multiple-ascending-dose data for oral SCY-247 reported
invasive fungal infectionssource ↗
▲IP Litigation RulingIP / Competition
Court granted motion to dismiss securities class action with leave to amend
Past FDA Catalysts and PDUFA Decisions
How SCYX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | SCY-770 | Phase 1 topline data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D29 / 100
Pipeline Score
$23M
Pipeline Value
$19M
Commercial Value
Fair Value
Valuation Signal
1
Drugs Scored
0.8x
rNPV / MCap
Top 72%
Micro Cap(rank 474 of 658)
Percentile Rank
SCYNEXIS, Inc. faces pipeline headwinds (29/100), with $470M risk-adjusted pipeline value, led by SCY-078 plus DAB in Candidiasis, Invasive (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $19.2M x 1.0 = $19M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| BREXAFEMME | $1M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SCY-078 plus DAB Small moleculeCompletedNCT03363841 | Candidiasis, Invasive | Phase 3 | COMPLETED | 30 | May 24, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every SCYX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SCY-770 Orphan | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 1 | 2026-10-06 | SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated. The Phase 1 study enrolled 25 healthy participants across three cohorts.Read More | SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Tinmouth Brian PhilippeDirector | Grant/Award | 2,875 2,875 held | $0.00 | 06/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SCYX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avidity Partners | 0.2 % (-50 %) | 1.06 M | 260.21 K | -87.5% ( -1.82 M) |
SCYX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SCYX ranks across every disease it competes in
Competitive Position is a premium feature
See how SCYX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSCYX News
SCYX▼ -11.7%today
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYNEXIS announced positive results from a Phase 1 study of SCY-770, a novel oral AMPK activator for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The study showed that SCY-770 was well tolerated at higher doses, supporting its safety profile. The company plans to initiate a Phase 2 proof-of-concept study in ADPKD patients in late 2026.
Read more →SCYX▲ +5.2%on this news· ran to +22% by day 3
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
SCYNEXIS has secured a contract with BARDA for up to $214 million to develop SCY-247, an antifungal therapy aimed at treating invasive fungal infections. This funding will support the advancement of SCY-247 into Phase 2 trials, enhancing the company's pipeline while maintaining its focus on SCY-770 for ADPKD. The partnership underscores the importance of addressing antimicrobial resistance in public health.
Read more →SCYX▲ +10.5%on this news
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
SCYNEXIS, Inc. has appointed Dr. Steven K. Burke to its Board of Directors, effective September 18, 2026. Dr. Burke brings over 30 years of experience in drug development, particularly for chronic kidney disease. His expertise is expected to support the advancement of SCY-770, a promising candidate for treating Autosomal Dominant Polycystic Kidney Disease, as the company prepares to enter Phase 2 trials.
Read more →SCYXSCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
SCYNEXIS has appointed Dr. Todd Minga as Senior Vice President of Research & Development, effective September 14, 2026. Dr. Minga, who has extensive experience in nephrology and drug development, will lead the company's initiatives in advancing treatments for rare diseases, particularly Autosomal Dominant Polycystic Kidney Disease. His appointment is seen as a strategic move to enhance SCYNEXIS's clinical portfolio.
Read more →SCYXSCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
SCYNEXIS, Inc. has appointed Sanjay Subramanian as Chief Financial Officer, effective September 9, 2026, following the retirement of Ivor Macleod. Subramanian brings over 20 years of experience in finance and business development, previously serving at Inozyme Pharma and Ocugen. His appointment aims to strengthen SCYNEXIS's financial position and support its strategic growth in developing therapies for severe rare diseases.
Read more →SCYXSCYNEXIS to Participate in Upcoming Investor Conferences
SCYNEXIS, Inc. announced its participation in two upcoming investor conferences, including the 12th Cantor Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The company focuses on developing therapies for severe diseases, with SCY-770 targeting Autosomal Dominant Polycystic Kidney Disease and having received Orphan Drug designation. A live webcast of the Cantor fireside chat will be available.
Read more →SCYX▲ +9.2%on this news
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SCYNEXIS, Inc. has announced the grant of an inducement equity award to a new Senior Director as part of their employment offer. The award includes stock options for 20,000 shares at an exercise price of $5.26, with a vesting schedule that encourages long-term commitment. This move aligns with Nasdaq Listing Rule 5635(c)(4) aimed at attracting new talent.
Read more →SCYX▼ -6.2%on this news
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SCYNEXIS reported its Q2 2026 financial results, highlighting the initiation of a Phase 1 study for SCY-770, aimed at treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company expects topline data in Q3 2026 and plans to start a Phase 2 trial in Q4 2026. Additionally, SCYNEXIS completed dosing for SCY-247's Phase 1 study, with data anticipated soon.
Read more →SCYX▲ +5.2%on this news· ran to +22% by day 3
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYNEXIS, Inc. has initiated a Phase 1 study of SCY-770, a novel AMPK activator aimed at treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The study will assess food effects and pharmacokinetics to inform dosing for a subsequent Phase 2 trial expected to start in Q4 2026. SCY-770 has shown promising preclinical results and has received Orphan Drug Designation from the FDA.
Read more →SCYX▼ -6.9%on this news
SCYNEXIS Announces One-for-Eight Reverse Stock Split - May 22, 2026
SCYNEXIS, Inc. announced a 1-for-8 reverse stock split effective May 29, 2026, to comply with Nasdaq listing requirements. The adjusted common stock will begin trading on June 1, 2026. The move aims to reduce the number of outstanding shares and enhance the company's market position. Stockholders will receive cash for any fractional shares.
Read more →SCYXSCYNEXIS Announces One-for-Eight Reverse Stock Split
SCYNEXIS, Inc. announced a 1-for-8 reverse stock split effective May 29, 2026. This action, approved by stockholders, aims to meet Nasdaq's minimum bid price requirement. Following the split, the number of authorized shares will decrease significantly, and stockholders will be compensated for any fractional shares in cash. The company's shares will start trading on June 1, 2026, under the existing symbol 'SCYX'.
Read more →SCYX▼ -10%on this news
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. reported strong first-quarter 2026 financial results, including a successful acquisition of SCY-770, a drug for autosomal dominant polycystic kidney disease (ADPKD). The company aims to commence a Phase 2 study for SCY-770 in Q4 2026, with early efficacy results expected by late 2027. Additionally, SCYNEXIS secured $37.2 million in a private placement, extending its financial runway to mid-2029. Progress is also being made on the antifungal drug SCY-247, with topline data anticipated later this year.
Read more →SCYXSCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SCYNEXIS, Inc. announced the approval of inducement equity awards for a new Vice President as part of their strategy to attract talent. The awards, consisting of stock options and restricted stock units, are intended to incentivize the new employee's acceptance of the position. This move aligns with the company's ongoing commitment to developing innovative therapies, particularly for rare diseases like Autosomal Dominant Polycystic Kidney Disease.
Read more →SCYX▲ +16.1%on this news
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYNEXIS, Inc. has completed the acquisition of PXL-770, now named SCY-770, a selective AMPK activator developed for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). This oral therapy aims to reduce cyst growth and has shown a favorable safety profile in clinical trials. With the anticipated launch of a Phase 2 study in Q4 2026, SCYNEXIS aims to address a significant unmet need in the ADPKD patient population. The acquisition includes an upfront payment, as well as potential milestone payments dependent on development progress.
Read more →SCYX▲ +16.1%on this news
SCYNEXIS Announces $40.0 million Private Placement
SCYNEXIS, Inc. has announced a $40 million private placement involving new and existing investors to fund ongoing operations and development of its therapies, particularly SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The agreement includes provisions for issuing common shares and warrants, potentially raising an additional $52.2 million if exercised. The closing of the deal is set for around April 1, 2026, but is contingent on certain closing conditions, including stockholder approval. The company aims to use the proceeds for working capital and has a projection of funding operations into mid-2029.
Read more →SCYX▲ +16.1%on this news
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
Poxel SA has announced a definitive agreement to sell PXL770 to Scynexis for up to $196 million. This deal is expected to bolster Poxel's financial position and support its ongoing development of treatments for metabolic diseases. The collaboration highlights the potential of PXL770 in addressing serious chronic conditions.
Read more →SCYX▲ +16.1%on this news
Advancing innovative solutions for severe rare diseases Corporate Deck March 2026 Legal Disclaimers This presentation has been prepared by SCYNEXIS, Inc. (the "Company") solely for informational purposes. This presentati
SCYNEXIS, Inc. has presented a corporate deck outlining its strategies for addressing severe rare diseases, specifically focusing on its product candidates SCY-770 and SCY-247. The company reported successful financing of $40M, strengthening its cash position and enabling the initiation of Phase 2 studies for SCY-770. This product targets Autosomal Dominant Polycystic Kidney Disease (ADPKD), a condition with a significant unmet medical need. Notably, the anticipated partnership with GSK on BREXAFEMME could lead to substantial sales milestones. However, risks associated with the company's forward-looking statements have been highlighted, emphasizing the uncertainties inherent in drug development.
Read more →SCYXSCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. reported its financial results for 2025, highlighting a significant increase in revenue primarily from a license agreement with GSK. The company is advancing its second-generation antifungal drug, SCY-247, and has secured a cash runway of over two years. Despite a decrease in total other income and cash balance, SCYNEXIS remains optimistic about future developments.
Read more →SCYXSCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
SCYNEXIS has announced the dosing of the first participants in a Phase 1 trial for SCY-247, an intravenous antifungal therapy aimed at treating invasive candidiasis. The drug has received both Qualified Infectious Disease Product and Fast Track designations from the FDA, highlighting its potential in addressing drug-resistant infections. Results from the trial are anticipated in 2026, following positive data from previous oral formulation studies.
Read more →SCYXSCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
SCYNEXIS, Inc. announced presentations on its second-generation fungicide, SCY-247, at the inaugural IMARI meeting in Las Vegas. The company emphasizes SCY-247's strong antifungal activity against resistant strains and its promising safety profile. The presentations will showcase the drug's potential role in combating deadly fungal infections, particularly those resistant to current treatments.
Read more →About SCYNEXIS, Inc.
Headquarters1 EVERTRUST PLAZA, JERSEY CITY, NJ, 07302-6548
BIOPHARMAWATCH ELITE PLUS
Trade the next SCYX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime